Humacyte Inc (HUMA)
Humacyte Inc is a biotechnology company listed on NASDAQ under the ticker HUMA. Through its subsidiaries, the company develops and manufactures bioengineered human tissues intended for use across several medical areas and anatomical sites. Its work centers on an in-house technology platform used to produce human acellular vessels, which are designed for implantation. Humacyte is building a portfolio of these vessels for applications that include vascular trauma, hemodialysis access, peripheral artery disease, pediatric cardiac surgery, coronary artery bypass grafting, and potential delivery of cellular therapies such as pancreatic islet cell transplantation for type 1 diabetes. The company was founded in 2004 and is based in Durham, North Carolina.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HUMA
|
$0.85
|
45.2% Upside
|
Undervalued
|
$1.85
|
217.3% Upside
|
Bargain
|
Weak
|
0.0%
|
November 6, 2026
|
5.2x
|
77.3x
|
161.9 M
|
150.9 M
|
29.2%
|
90.4%
|
-9.0
|
100.9%
|
